case_images: PMC3398337_01
case_images: Abdominal MRI scans of patient 1 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
case_images: 1752-1947-6-2-1.jpg
case_images: PMC3398337_01_1752-1947-6-2-1.jpg
case_images: F1
case_images: The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4).
case_images: Abdominal MRI scans of patient 2 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
case_images: 1752-1947-6-2-2.jpg
case_images: PMC3398337_01_1752-1947-6-2-2.jpg
case_images: F2
case_images: The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4). Body fat thickness also increased in the flanks and back areas (only in patient 2; Figure 2) and the posterior surface of the thighs in both patients (Figures 3 and 4).
case_images: MRI scans of the thighs of patient 1 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
case_images: 1752-1947-6-2-3.jpg
case_images: PMC3398337_01_1752-1947-6-2-3.jpg
case_images: F3
case_images: The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4). Body fat thickness also increased in the flanks and back areas (only in patient 2; Figure 2) and the posterior surface of the thighs in both patients (Figures 3 and 4).
case_images: MRI scans of the thighs of patient 2 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
case_images: 1752-1947-6-2-4.jpg
case_images: PMC3398337_01_1752-1947-6-2-4.jpg
case_images: F4
case_images: The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4). Body fat thickness also increased in the flanks and back areas (only in patient 2; Figure 2) and the posterior surface of the thighs in both patients (Figures 3 and 4).